 Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis Positive Interim 6-Month Bone Mineral Density BMD Data Reported in Phase 2 EB613 Clinical Trial Company Expect s to Report Bio m arker Data that Includes the 2.5 mg Dose in Q1:21 and Final Data from The Phase 2 Trial Including BMD in Q2: 21 Company to Host Conference Call and Webcast Today at 8:30 a.m. ET 